XML 28 R17.htm IDEA: XBRL DOCUMENT v3.26.3
EQUITY
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
EQUITY

NOTE 7 - EQUITY

 

  a. Authorized Capital Stock
     
    As of September 30, 2026, the Company had 255,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 250,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.
     
  b. Preferred Stock
     
   

As of September 30, 2026, there were 1,718 shares of Series C preferred stock outstanding, convertible into an aggregate of 14,328 shares of the Company’s common stock, with a total stated value of $10,997.

 

Pursuant to the full ratchet anti-dilution adjustment provisions in the certificate of designation for the Company’s Series C preferred stock, following the Warrant Amendments described in Note 7d, the conversion price of the outstanding shares of Series C preferred stock was reduced from $1.3827 to $0.7674 per share, effective as of September 21, 2026, and the number of shares of common stock issuable upon conversion of the Series C preferred stock increased by 6,376 additional shares, to an aggregate of 14,328 shares.

 

  c. Pre-Funded Warrants
     
    As of September 30, 2026, there were 42,188,078 outstanding pre-funded warrants.

 

 

  d. Warrants
     
    On September 21, 2026, the Company entered into amendments (the “Warrant Amendments”) with certain holders of its outstanding Series J and Series K warrants (collectively, the “Existing Warrants”). Pursuant to the Warrant Amendments, the Company amended Series J warrants covering 4,771,980 shares, representing 50% of the shares underlying the participating holders’ Series J warrants, and Series K warrants covering 9,543,947 shares, representing all of the shares underlying the participating holders’ Series K warrants. The Warrant Amendments reduced the exercise price of the amended warrants from $1.3827 per share to $0.7674 per share (less $0.0001 for holders that elect to receive pre-funded warrants upon exercise) and revised their expiration date to the earlier of May 15, 2028 and 20 trading days following the Company’s announcement of receipt of FDA approval for CGuard Prime 80 cm. The exercise price and expiration date of the remaining 50% of the participating holders’ Series J warrants remained unchanged. All terms and conditions of Series J and Series K warrants held by holders that did not enter into the Warrant Amendments also remained unchanged and in full force and effect. All other terms and conditions of the Existing Warrants remained unchanged and in full force and effect.
     
   

The Company accounted for the Warrant Amendments as modifications of equity-classified warrants and measured the modification effect as the excess of fair value immediately after modification over fair value immediately before modification. The resulting incremental fair value of $684 thousand was recognized as a deemed dividend for the three and nine months ended September 30, 2026. The deemed dividend did not affect net loss or total equity, but increased loss available to common stockholders and basic and diluted net loss per share. In addition, as a result of the Warrant Amendments, the conversion price of the Series C preferred stock was adjusted pursuant to its anti-dilution provisions. See Note 7b.

 

As of September 30, 2026, the Company has outstanding warrants to purchase an aggregate of 25,828,164 shares of common stock as follows:

 

Classification  Series J   Series K  

Total warrants

amount

   Exercise
price
   Expiration
date
 
Amended   4,771,980    9,543,947    14,315,927   $0.7674    * 
Unamended   8,142,106    3,370,131    11,512,237   $1.3827    * 
Total   12,914,086    12,914,078    25,828,164    —    — 

 

*Amended Series J warrants and Amended Series K warrants: expire on the earlier of May 15, 2028 and 20 trading days after the Company announces FDA approval for CGuard Prime 80 cm.

 

Unamended Series J warrants: expire on the earlier of May 15, 2028 and 20 trading days following the Company’s announcement of receipt of FDA approval for SwitchGuard and CGuard Prime 80 cm.

 

Unamended Series K warrants: expire on the earlier of May 15, 2028 and 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime 135 cm in the U.S. began. Subsequent to that date, the unamended Series K warrants expired unexercised on October 28, 2026.

 

On November 12, 2026, the Company announced FDA approval for CGuard Prime 80 cm. Accordingly, the amended Series J warrants and amended Series K warrants will expire on December 11, 2026, which is 20 trading days after the announcement, unless exercised prior to that date.

 

During the nine months ended September 30, 2026, a total of 1,092,344 Series G warrants expired unexercised.

 

  e. Share-Based Compensation
     
    During the nine months ended September 30, 2026, the Company granted 4,694,476 restricted shares of common stock to employees and directors. Employee awards generally vest over three years, typically in annual installments, although certain employee awards vest over one year or have individualized vesting schedules, subject to continued service. Director awards vest over one year, subject to continued service.
     
    The fair value of the above restricted shares was approximately $6.6 million.
     
   

During the nine months ended September 30, 2026, the Company granted 1,114,792 restricted stock units convertible into shares of the Company’s common stock to the Company’s chief executive officer. The restricted stock units are subject to a three-year vesting period, with one-third of such awards vesting each year, subject to continued service.

     
    The fair value of the above restricted stock units was approximately $1.8 million